| Description : |
This gene is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes, including cell division, adhesion, differentiation, and response to stress. The activity of the protein is negatively regulated by its SH3 domain, whereby deletion of the region encoding this domain results in an oncogene. The ubiquitously expressed protein has DNA-binding activity that is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. This gene has been found fused to a variety of translocation partner genes in various leukemias, most notably the t(9;22) translocation that results in a fusion with the 5' end of the breakpoint cluster region gene (BCR; MIM:151410). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons that are spliced to the remaining common exons. |
| Source : |
Sf21 |
| Species : |
Human |
| Tag : |
His |
| Protein length : |
27–end, T315I |
| Form : |
1.948mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1mM EGTA, 0.1% 2-mercaptoethanol, 0.03% Brij-35. Frozen solution. |
| Bio-activity : |
743U/mg, where one unit of Abl (T315I), active activity is defined as 1nmol phosphate incorporated into 50μM Abltide (EAIYAAPFAKKK) per minute at 30 centigrade with a final ATP concentration of 100μM. |
| Molecular Mass : |
121.4 kDa |
| AA Sequence : |
1 MHHHHHHEFE ALQRPVASDF EPQGLSEAAR WNSKENLLAG PSENDPNLFV ALYDFVASGD 61 NTLSITKGEK LRVLGYNHNG EWCEAQTKNG QGWVPSNYIT PVNSLEKHSW YHGPVSRNAA 121 EYLLSSGING SFLVRESESS PGQRSISLRY EGRVYHYRIN TASDGKLYVS SESRFNTLAE 181 LVHHHSTVAD GLITTLHYPA PKRNKPTVYG VSPNYDKWEM ERTDITMKHK LGGGQYGEVY 241 EGVWKKYSLT VAVKTLKEDT MEVEEFLKEA AVMKEIKHPN LVQLLGVCTR EPPFYIIIEF 301 MTYGNLLDYL RECNRQEVNA VVLLYMATQI SSAMEYLEKK NFIHRDLAAR NCLVGENHLV 361 KVADFGLSRL MTGDTYTAHA GAKFPIKWTA PESLAYNKFS IKSDVWAFGV LLWEIATYGM 421 SPYPGIDLSQ VYELLEKDYR MERPEGCPEK VYELMRACWQ WNPSDRPSFA EIHQAFETMF 481 QESSISDEVE KELGKQGVRG AVSTLLQAPE LPTKTRTSRR AAEHRDTTDV PEMPHSKGQG 541 ESDPLDHEPA VSPLLPRKER GPPEGGLNED ERLLPKDKKT NLFSALIKKK KKTAPTPPKR 601 SSSFREMDGQ PERRGAGEEE GRDISNGALA FTPLDTADPA KSPKPSNGAG VPNGALRESG 661 GSGFRSPHLW KKSSTLTSSR LATGEEEGGG SSSKRFLRSC SASCVPHGAK DTEWRSVTLP 721 RDLQSTGRQF DSSTFGGHKS EKPALPRKRA GENRSDQVTR GTVTPPPRLV KKNEEAADEV 781 FKDIMESSPG SSPPNLTPKP LRRQVTVAPA SGLPHKEEAG KGSALGTPAA AEPVTPTSKA 841 GSGAPGGTSK GPAEESRVRR HKHSSESPGR DKGKLSRLKP APPPPPAASA GKAGGKPSQS 901 PSQEAAGEAV LGAKTKATSL VDAVNSDAAK PSQPGEGLKK PVLPATPKPQ SAKPSGTPIS 961 PAPVPSTLPS ASSALAGDQP SSTAFIPLIS TRVSLRKTRQ PPERIASGAI TKGVVLDSTE 1021 ALCLAISRNS EQMASHSAVL EAGKNLYTFC VSYVDSIQQM RNKFAFREAI NKLENNLREL 1081 QICPATAGSG PAATQDFSKL LSSVKEISDI VQR |
| Purity : |
Purity 27% by SDS-PAGE and Coomassie staining. |
| Applications : |
Drug Discovery & Development |
| Storage : |
6 months at -70 centigrade. |
| Handling Advice : |
Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into prechilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70 centigrade. |
| Use/Stability : |
On receipt of material store at -70 centigrade. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap. |
